Q2 2024 Fulgent Genetics Inc Earnings Call Transcript
Key Points
- Fulgent Genetics Inc (FLGT) reported a total revenue of $71 million for Q2 2024, showing growth from $67.9 million in Q2 2023.
- Core revenue, excluding COVID-19 tests, was $70.2 million, driven by strong performance in precision diagnostics, reproductive health, and oncology.
- The company achieved a significant milestone with the consolidation of labs acquired through the informed diagnosis transaction, enhancing future growth potential.
- Fulgent Genetics Inc (FLGT) has initiated a Phase 2 clinical trial for its lead therapeutic candidate FID-007, showing promising preliminary results in treating head and neck cancer.
- The company maintains a strong balance sheet with approximately $838 million in cash, cash equivalents, and marketable securities, providing a solid foundation for future investments and growth.
- Despite the revenue growth, the company reported a GAAP operating expense increase to $45.4 million in Q2 2024, up from $43.9 million in Q1 2024, primarily due to higher R&D spending.
- Non-GAAP operating margins were negative at -7.4%, indicating ongoing challenges in achieving profitability.
- The company anticipates a non-GAAP operating margin of approximately -16% for the full year 2024, reflecting continued investment needs.
- The therapeutic development business is expected to incur a cash burn of $15 million to $17 million in 2024, impacting overall financial performance.
- Uncertainty around new FDA regulations on lab-developed tests could pose potential challenges and disruptions to the company's service offerings.
Hello and welcome to the Fulgent Genetics Q2 2024 Conference Call and Webcast. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the conference over to Melanie Solomon, Investor Relations. Please go ahead, Melanie.
Thank you, Kevin. Good morning and welcome to the Fulgent second-quarter of 2024 financial results conference call. On the call today are Ming Hsieh, Chief Executive Officer; Paul Kim, Chief Financial Officer; and Brandon Perthuis, Chief Commercial Officer.
The company's press release discussing the financial results is available on the Investor Relations section of the company's website, www.fulgentgenetics.com. A replay of this call will be available shortly after the call concludes on the Invest Relations section of the company's website.
Management's prepared remarks and answers to your questions on today's call will contain forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
